ClinicalTrials.gg
CompletedNCT02293902Updated Jan 30, 2018Results posted

A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)

A Phase 3 interventional study of Sarilumab SAR153191 (REGN88) and Placebo (for sarilumab) in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 96 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-01-30.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
43rd of 113
243 · median 130
Started
2014
with 1 other
Phase 3
47 of 113
1 open now
Registered
81st of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 43rd largest by enrollment, is one of 2 that started in 2014, is one of 47 in phase 3, and was the 81st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

-To demonstrate that sarilumab added to methotrexate (MTX) reduce signs and symptoms of rheumatoid arthritis (RA) in Japanese RA participants with an inadequate response to MTX.

Secondary Objective:

-To assess the safety of sarilumab added to MTX in Japanese RA participants with an inadequate response to MTX.

Read the detailed description

The total duration of study was expected up to 62 weeks (screening period of 4 weeks, treatment period of 52 weeks, and a 6-week post treatment observation).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA, according to the American College of Rheumatology/The European League Against Rheumatism (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria with >=3 months disease duration.
  • Moderately to severely active RA defined as:
  • At least 8 of 68 tender joints and 6 of 66 swollen joints at screening visit.
  • High sensitivity C-Reactive Protein (hs-CRP) >=6mg/L at screening visit.

Exclusion criteria

Exclusion criteria:

  • Participants \<20 or >75 years of age.
  • Treatment with any Disease-modifying antirheumatic drug (DMARD) other than MTX or biologic agent without the appropriate off-drug period prior to screening.
  • Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Sarilumab 150 mg/150 mg

    Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either tender joint count \[TJC\] or swollen joint count \[SJC\], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.

    Drug: Sarilumab SAR153191 (REGN88) · Drug: Methotrexate · Drug: Folic acid

  • Experimental
    Sarilumab 200 mg/200 mg

    Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.

    Drug: Sarilumab SAR153191 (REGN88) · Drug: Methotrexate · Drug: Folic acid

  • Placebo comparator
    Placebo/Sarilumab 150 mg

    Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.

    Drug: Sarilumab SAR153191 (REGN88) · Other: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic acid

  • Placebo comparator
    Placebo/Sarilumab 200 mg

    Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.

    Drug: Sarilumab SAR153191 (REGN88) · Other: Placebo (for sarilumab) · Drug: Methotrexate · Drug: Folic acid

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • OtherPlacebo (for sarilumab)

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • Dispensed according to local practice.

  • Dispensed according to local practice.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24

    American College of Rheumatology (ACR) response is a composite rating scale that includes 7 variables: tender joints count (TJC \[68 joints\]); Swollen joints count (SJC \[66 joints\]); levels of an acute phase reactant (high sensitivity C-reactive protein \[hs-CRP level\]); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by health assessment questionnaire disability index \[HAQ-DI\], with scoring range of 0 \[better health\] - 3 \[worst health\]). ACR20 response was defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments.

    Time frame: Week 24

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AEs that developed or worsened or became serious during double-blind on-treatment period, single-blind on-treatment period up to 6-week post-treatment follow-up period (up to Week 58) were considered treatment-emergent.

    Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58

  2. Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities

    Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure supine (SBP\[S\]): \<=95 mmHg and decrease from baseline (DFB) \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure supine (DBP\[S\]): \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg * Orthostatic systolic blood pressure (SBP\[O\]): \<=-20 mmHg * Orthostatic diastolic blood pressure (DBP\[O\]): \<=-10 mmHg * Heart rate supine (HR\[S\]): \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB

    Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58

  3. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

    Criteria for potentially clinically significant ECG abnormalities: * PR Interval: \>200 millisecond (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QT Interval: \>500 ms * QTc Bazett (QTc B): \>450 ms; 480 ms; 500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; 480 ms; 500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms

    Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58

  4. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters

    Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female\[F\]); \>=185 g/L (M) or \>=165 g/L (F); DFB \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<50 Giga/L; \>=50 and \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black\[NB\]) or \<2.0 Giga/L (Black\[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \<0.5 Giga/L; \>=0.5 Giga/L and \< lower limit of normal (LLN); \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)

    Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58

  5. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters

    Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L unfasted or \>=7 mmol/L fasted * Hemoglobin A1c (HbA1c): \>8% * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L

    Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58

  6. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes

    Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L

    Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58

  7. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters

    Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L; \>=30% change from baseline; \>=100% change from baseline * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \< 60 mL/min; \>=60 to \<90 mL/min * Blood urea nitrogen: \>=17 mmol/L * Uric acid: \<120 micromol/L; \>408 micromol/L

    Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58

  8. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

    Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN * Conjugated bilirubin (CBILI): \>1.5 ULN; \>2 ULN * Unconjugated bilirubin: \>1.5 ULN; \>2 ULN * ALT and TBILI: ALT \>3 ULN and TBILI \>2 ULN * CBILI and TBILI: CBILI \>35% TBILI and TBILI \>1.5 ULN * Albumin: \<=25 g/L

    Time frame: For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm : Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58

07

Results

Posted Jan 30, 2018

Participant flow

The study was conducted at 95 centers in Japan between 06 November 2014 and 28 October 2016. A total of 388 participants were screened, of whom 243 participants were randomized and 145 were screen failures.

Double-Blind Period (Up to Week 24)
Participant flow — Double-Blind Period (Up to Week 24)
MilestonePlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mg
Started82818000
Treated81818000
Rescued446800
Completed71747000
Not completed1171000
Withdrew: Adverse event56800
Withdrew: Lack of efficacy51200
Withdrew: Randomized but not treated10000
Single-Blind Period (Week 25 to Week 52)
Participant flow — Single-Blind Period (Week 25 to Week 52)
MilestonePlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mg
Started074703437
Completed066683331
Not completed08216
Withdrew: Adverse event07116
Withdrew: Lack of efficacy01100

Outcome measures

PrimaryPercentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24

American College of Rheumatology (ACR) response is a composite rating scale that includes 7 variables: tender joints count (TJC \[68 joints\]); Swollen joints count (SJC \[66 joints\]); levels of an acute phase reactant (high sensitivity C-reactive protein \[hs-CRP level\]); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by health assessment questionnaire disability index \[HAQ-DI\], with scoring range of 0 \[better health\] - 3 \[worst health\]). ACR20 response was defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24
percentage of participantsPlaceboSarilumab 150 mgSarilumab 200 mg
Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 2414.867.957.5
Statistical analysis
  • Placebo vs Sarilumab 150 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 12.185 · 95% CI 5.583 to 26.594
  • Placebo vs Sarilumab 200 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 7.227 · 95% CI 3.446 to 15.158
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AEs that developed or worsened or became serious during double-blind on-treatment period, single-blind on-treatment period up to 6-week post-treatment follow-up period (up to Week 58) were considered treatment-emergent.

Time frame:
For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
Treatment Emergent AEs497671121354
Treatment Emergent SAEs685024
SecondaryNumber of Participants With Potentially Clinically Significant Vital Signs Abnormalities

Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure supine (SBP\[S\]): \<=95 mmHg and decrease from baseline (DFB) \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure supine (DBP\[S\]): \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg * Orthostatic systolic blood pressure (SBP\[O\]): \<=-20 mmHg * Orthostatic diastolic blood pressure (DBP\[O\]): \<=-10 mmHg * Heart rate supine (HR\[S\]): \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB

Time frame:
For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
participantsPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
SBP(S) <=95 mmHg and DFB >=20 mmHg241000
SBP(S) >=160 mmHg and IFB >=20 mmHg255018
DBP(S) <=45 mmHg and DFB >=10 mmHg111000
DBP(S)>=110 mmHg and IFB >=10 mmHg010000
SBP(O) <=-20 mmHg821232212
DBP(O) <=-10 mmHg817120110
HR(S) <=50 bpm and DFB >=20 bpm041001
HR(S) >=120 bpm and IFB >=20 bpm100000
Weight >=5% DFB557004
Weight >=5% IFB531277615
SecondaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

Criteria for potentially clinically significant ECG abnormalities: * PR Interval: \>200 millisecond (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QT Interval: \>500 ms * QTc Bazett (QTc B): \>450 ms; 480 ms; 500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; 480 ms; 500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms

Time frame:
For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
participantsPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
PR Interval >200 ms695026
PR Interval >200 ms and IFB >=25%010000
PR Interval >220 ms342012
PR Interval >220 ms and IFB >=25%010000
PR Interval >240 ms210012
PR Interval >240 ms and IFB >=25%000000
QRS Interval >110 ms222113
QRS Interval >110 ms and IFB >=25%000001
QRS Interval >120 ms221112
QRS Interval >120 ms and IFB >=25%000001
QT Interval >500 ms101003
QTc B >450 ms1216222318
QTc B >480 ms022012
QTc B >500 ms000000
QTc B IFB >30 and <=60 ms222015
QTc B IFB >60 ms000000
QTc F>450 ms711140212
QTc F>480 ms000011
QTc F>500 ms000000
QTc F IFB >30 and <=60 ms443013
QTc F IFB >60 ms000000
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters

Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female\[F\]); \>=185 g/L (M) or \>=165 g/L (F); DFB \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<50 Giga/L; \>=50 and \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black\[NB\]) or \<2.0 Giga/L (Black\[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \<0.5 Giga/L; \>=0.5 Giga/L and \< lower limit of normal (LLN); \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)

Time frame:
For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters
participantsPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
Hemoglobin <=115 g/L (M) or <=95 g/L (F)945015
Hemoglobin >=185 g/L (M) or >=165 g/L (F)000000
Hemoglobin DFB >=20 g/L403001
Hematocrit <=0.37 v/v (M) or <=0.32 v/v (F)171014036
Hematocrit >=0.55 v/v (M) or >=0.5 v/v (F)000000
RBC >=6 Tera/L000000
Platelets <50 Giga/L010000
Platelets >=50 and <100 Giga/L024001
Platelets >=700 Giga/L100000
WBC <3.0 Giga/L (NB) or <2.0 Giga/L (B)030235617
WBC >=16.0 Giga/L055002
Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B)031245618
Neutrophils <1.0 Giga/L0116308
Lymphocytes <0.5 Giga/L363121
Lymphocytes >=0.5 Giga/L and <LLN2329324218
Lymphocytes >4.0 Giga/L000000
Monocytes >0.7 Giga/L9107023
Basophils >0.1 Giga/L6119109
Eosinophils>0.5 Giga/L or >ULN(if ULN>=0.5 Giga/L)121102
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters

Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L unfasted or \>=7 mmol/L fasted * Hemoglobin A1c (HbA1c): \>8% * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L

Time frame:
For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters
participantsPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
Glucose <=3.9 mmol/L and <LLN002112
Glucose>=11.1 mmol/L unfasted or >=7 mmol/L fasted384001
HbA1c >8%000000
Total cholesterol >=6.2 mmol/L940324217
Total cholesterol >=7.74 mmol/L075013
LDL cholesterol >=4.1 mmol/L32017317
LDL cholesterol >=4.9 mmol/L046012
Triglycerides >=4.6 mmol/L003012
Triglycerides >=5.6 mmol/L003012
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes

Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L

Time frame:
For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes
participantsPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
Sodium <=129 mmol/L001000
Sodium >=160 mmol/L001001
Potassium <3 mmol/L001000
Potassium >=5.5 mmol/L002010
Chloride <80 mmol/L000000
Chloride >115 mmol/L000001
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters

Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L; \>=30% change from baseline; \>=100% change from baseline * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \< 60 mL/min; \>=60 to \<90 mL/min * Blood urea nitrogen: \>=17 mmol/L * Uric acid: \<120 micromol/L; \>408 micromol/L

Time frame:
For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters
participantsPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
Creatinine >=150 micromol/L011010
Creatinine >=30% change from baseline518220417
Creatinine >=100% change from baseline011010
Creatinine clearance <15 mL/min000000
Creatinine clearance >=15 to <30 mL/min010010
Creatinine clearance >=30 to <60 mL/min61214027
Creatinine clearance >=60 to <90 mL/min4145427535
Blood urea nitrogen >=17 mmol/L000010
Uric acid <120 micromol/L012000
Uric acid >408 micromol/L81314335
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN * Conjugated bilirubin (CBILI): \>1.5 ULN; \>2 ULN * Unconjugated bilirubin: \>1.5 ULN; \>2 ULN * ALT and TBILI: ALT \>3 ULN and TBILI \>2 ULN * CBILI and TBILI: CBILI \>35% TBILI and TBILI \>1.5 ULN * Albumin: \<=25 g/L

Time frame:
For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm : Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
participantsPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
ALT >1 ULN and <=1.5 ULN317243616
ALT >1.5 ULN and <=3 ULN72419449
ALT >3 ULN and <=5 ULN6115204
ALT >5 ULN and <=10 ULN012012
ALT >10 ULN and <=20 ULN000000
ALT >20 ULN000000
AST >1 ULN and <=1.5 ULN734326822
AST >1.5 ULN and <=3 ULN1118103111
AST >3 ULN and <=5 ULN152113
AST >5 ULN and <=10 ULN001000
AST >10 ULN and <=20 ULN000000
AST >20 ULN000000
Alkaline phosphatase >1.5 ULN020000
TBILI >1.5 ULN012103
TBILI >2 ULN001001
CBILI >1.5 ULN000001
CBILI >2 ULN000001
Unconjugated bilirubin >1.5 ULN001001
Unconjugated bilirubin >2 ULN000000
ALT >3 ULN and TBILI >2 ULN000000
CBILI >35% TBILI and TBILI >1.5000001
Albumin <=25 g/L000000

Adverse events

Collected over For placebo arm: Baseline up to Week 24; For sarilumab 150 mg/150 mg, sarilumab 200 mg/200 mg and sarilumab rescue arm: Baseline up to Week 58; For placebo/sarilumab 150 mg and placebo/sarilumab 200 mg arm: Week 25 up to Week 58.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/81 (7.4%)35/81 (43.2%)
Sarilumab 150 mg/150 mg—8/81 (9.9%)67/81 (82.7%)
Sarilumab 200 mg/200 mg—5/80 (6.3%)59/80 (73.8%)
Placebo/Sarilumab 150 mg—0/14 (0%)12/14 (85.7%)
Placebo/Sarilumab 200 mg—2/15 (13.3%)13/15 (86.7%)
Sarilumab Rescue—4/58 (6.9%)48/58 (82.8%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
Pneumocystis jirovecii pneumoniaInfections and infestations0/811/810/800/141/150/58
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/810/810/800/141/150/58
Venous thrombosis limbVascular disorders0/810/810/800/141/150/58
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/810/810/800/140/150/58
LeukopeniaBlood and lymphatic system disorders0/810/810/800/140/151/58
Gastroenteritis bacterialInfections and infestations0/810/810/800/140/151/58
Pneumonia pneumococcalInfections and infestations0/810/810/800/140/151/58
OsteoporosisMusculoskeletal and connective tissue disorders0/810/810/800/140/151/58
Macular fibrosisEye disorders0/810/811/800/140/150/58
Radius fractureInjury, poisoning and procedural complications0/810/811/800/140/150/58
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgPlacebo/Sarilumab 150 mgPlacebo/Sarilumab 200 mgSarilumab Rescue
NasopharyngitisInfections and infestations12/8127/8123/805/144/1519/58
Alanine aminotransferase increasedInvestigations4/817/814/803/140/153/58
NeutropeniaBlood and lymphatic system disorders0/8110/819/802/141/156/58
StomatitisGastrointestinal disorders3/816/818/802/141/157/58
LeukopeniaBlood and lymphatic system disorders0/812/811/800/142/151/58
DiarrhoeaGastrointestinal disorders0/812/812/800/142/154/58
Upper respiratory tract infectionInfections and infestations4/818/817/800/140/156/58
Injection site erythemaGeneral disorders0/818/817/801/140/155/58
Hepatic function abnormalHepatobiliary disorders4/818/817/800/140/154/58
EczemaSkin and subcutaneous tissue disorders1/817/814/801/140/153/58

Baseline characteristics

Analysis was performed on randomized population which included all participants who had been allocated to a randomized treatment regardless of whether the treatment was actually administered.

Age, Continuous
Age, Continuous(years)PlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgTotal
Mean53.4 ± 11.556.1 ± 9.555.3 ± 11.054.9 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSarilumab 150 mg/150 mgSarilumab 200 mg/200 mgTotal
Female656361189
Male17181954
08

Study locations

96 sites
  • Investigational Site Number 392010
    Asahi-Shi, Japan
  • Investigational Site Number 392001
    Asahikawa-Shi, Japan
  • Investigational Site Number 392035
    Asahikawa-Shi, Japan
  • Investigational Site Number 392070
    Beppu-Shi, Japan
  • Investigational Site Number 392036
    Chiba-Shi, Japan
  • Investigational Site Number 392083
    Chuo-Ku, Japan
  • Investigational Site Number 392047
    Fuchu-Shi, Japan
  • Investigational Site Number 392004
    Fukui-Shi, Japan
  • Investigational Site Number 392007
    Fukuoka-Shi, Japan
  • Investigational Site Number 392038
    Fukuoka-Shi, Japan
  • Investigational Site Number 392039
    Fukuoka-Shi, Japan
  • Investigational Site Number 392078
    Fukushima-Shi, Japan
  • Investigational Site Number 392054
    Funabashi-Shi, Japan
  • Investigational Site Number 392015
    Hachioji-Shi, Japan
  • Investigational Site Number 392085
    Hannan-Shi, Japan
  • Investigational Site Number 392091
    Hiroshima-Shi, Japan
  • Investigational Site Number 392098
    Hiroshima-Shi, Japan
  • Investigational Site Number 392009
    Hitachinaka-Shi, Japan
  • Investigational Site Number 392011
    Hitachinaka-Shi, Japan
  • Investigational Site Number 392030
    Ichinomiya-Shi, Japan
  • Investigational Site Number 392002
    Iizuka-Shi, Japan
  • Investigational Site Number 392019
    Kagoshima-Shi, Japan
  • Investigational Site Number 392066
    Kamakura-Shi, Japan
  • Investigational Site Number 392086
    Kamogawa-Shi, Japan
  • Investigational Site Number 392050
    Kato-Shi, Japan
  • Investigational Site Number 392037
    Kawachi-Nagano-Shi, Japan
  • Investigational Site Number 392093
    Kawagoe-Shi, Japan
  • Investigational Site Number 392099
    Kawasaki-Shi, Japan
  • Investigational Site Number 392016
    Kirishima-Shi, Japan
  • Investigational Site Number 392013
    Kitakyushu-Shi, Japan
  • Investigational Site Number 392024
    Kitakyushu-Shi, Japan
  • Investigational Site Number 392045
    Kitakyushu-Shi, Japan
  • Investigational Site Number 392063
    Kiyose-Shi, Japan
  • Investigational Site Number 392051
    Kobe-Shi, Japan
  • Investigational Site Number 392097
    Kochi-Shi, Japan
  • Investigational Site Number 392040
    Koushi-Shi, Japan
  • Investigational Site Number 392069
    Kumamoto-Shi, Japan
  • Investigational Site Number 392089
    Kurashiki-Shi, Japan
  • Investigational Site Number 392065
    Kushiro-Shi, Japan
  • Investigational Site Number 392026
    Matsuyama-Shi, Japan
  • Investigational Site Number 392081
    Matsuyama-Shi, Japan
  • Investigational Site Number 392094
    Matsuyama-Shi, Japan
  • Investigational Site Number 392042
    Meguro-Ku, Japan
  • Investigational Site Number 392082
    Meguro-Ku, Japan
  • Investigational Site Number 392012
    Mito-Shi, Japan
  • Investigational Site Number 392034
    Miyagi-Gun, Japan
  • Investigational Site Number 392053
    Morioka-Shi, Japan
  • Investigational Site Number 392032
    Nagano-Shi, Japan
  • Investigational Site Number 392064
    Nagasaki-Shi, Japan
  • Investigational Site Number 392043
    Nagoya-Shi, Japan
  • Investigational Site Number 392056
    Nagoya-Shi, Japan
  • Investigational Site Number 392076
    Nagoya-Shi, Japan
  • Investigational Site Number 392080
    Nagoya-Shi, Japan
  • Investigational Site Number 392031
    Nakano-Ku, Japan
  • Investigational Site Number 392046
    Narashino-Shi, Japan
  • Investigational Site Number 392067
    Narashino-Shi, Japan
  • Investigational Site Number 392044
    Nishinomiya-Shi, Japan
  • Investigational Site Number 392059
    Oita-Shi, Japan
  • Investigational Site Number 392062
    Okayama-Shi, Japan
  • Investigational Site Number 392008
    Omura-Shi, Japan
  • Investigational Site Number 392057
    Osaka-Shi, Japan
  • Investigational Site Number 392060
    Osaka-Shi, Japan
  • Investigational Site Number 392061
    Osaka-Shi, Japan
  • Investigational Site Number 392096
    Osaka-Shi, Japan
  • Investigational Site Number 392027
    Osaki-Shi, Japan
  • Investigational Site Number 392049
    Sagamihara-Shi, Japan
  • Investigational Site Number 392072
    Saitama-Shi, Japan
  • Investigational Site Number 392075
    Sakai-Shi, Japan
  • Investigational Site Number 392014
    Sapporo-Shi, Japan
  • Investigational Site Number 392068
    Sapporo-Shi, Japan
  • Investigational Site Number 392073
    Sapporo-Shi, Japan
  • Investigational Site Number 392006
    Sasebo-Shi, Japan
  • Investigational Site Number 392021
    Sendai-Shi, Japan
  • Investigational Site Number 392022
    Sendai-Shi, Japan
  • Investigational Site Number 392033
    Sendai-Shi, Japan
  • Investigational Site Number 392071
    Sendai-Shi, Japan
  • Investigational Site Number 392100
    Sendai-Shi, Japan
  • Investigational Site Number 392029
    Shizuoka-Shi, Japan
  • Investigational Site Number 392025
    Sumida-Ku, Japan
  • Investigational Site Number 392092
    Sumida-Ku, Japan
  • Investigational Site Number 392023
    Takaoka-Shi, Japan
  • Investigational Site Number 392095
    Takarazuka-Shi, Japan
  • Investigational Site Number 392020
    Takasaki-Shi, Japan
  • Investigational Site Number 392088
    Takatsuki-Shi, Japan
  • Investigational Site Number 392018
    Tokorozawa-Shi, Japan
  • Investigational Site Number 392003
    Tomakomai-Shi, Japan
  • Investigational Site Number 392005
    Tomakomai-Shi, Japan
  • Investigational Site Number 392077
    Tonami-Shi, Japan
  • Investigational Site Number 392052
    Toshima-Ku, Japan
  • Investigational Site Number 392058
    Toyama-Shi, Japan
  • Investigational Site Number 392055
    Toyonaka-Shi, Japan
  • Investigational Site Number 392074
    Urasoe-Shi, Japan
  • Investigational Site Number 392079
    Urayasu-Shi, Japan
  • Investigational Site Number 392048
    Yokohama-Shi, Japan
  • Investigational Site Number 392090
    Yokohama-Shi, Japan
  • Investigational Site Number 392101
    Yokohama-Shi, Japan
09

References and documents

Publications

  • Tanaka Y, Takahashi T, Van Hoogstraten H, Praestgaard A, Kato N, Kameda H. Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab. Clin Exp Rheumatol. 2023 May;41(5):1129-1139. doi: 10.55563/clinexprheumatol/jq9u8f. Epub 2022 Oct 28. PubMed 36305354 ↗
  • Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham NMH, Kameda H. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019 Mar 20;21(1):79. doi: 10.1186/s13075-019-1856-4. Erratum In: Arthritis Res Ther. 2019 Apr 16;21(1):99. doi: 10.1186/s13075-019-1887-x. PubMed 30894208 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2014
First posted
Nov 19, 2014
Start
Nov 2014
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Results first posted
Jan 30, 2018
Last update
Jan 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02293902
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 19, 2014
Start date
Nov 2014
Primary completion
Oct 2016
Completion
Oct 2016
Results posted
Jan 30, 2018
Last update
Jan 30, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion